Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Five RNAi-Related Patent Applications: Jul 12, 2007

Premium
Title: RNAi-Mediated Inhibition of HIF1A for Treatment of Ocular Disorders
 
Number: 20070155690
 
Filed: Dec. 19, 2006
 
Lead Inventor: Jon Chatterton, Alcon
 
According to its abstract, the patent application claims “RNA interference … for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization, and neovascular glaucoma, and for treating patients at risk of developing such conditions.”
 

 
Title: RNAi Modulation of HIF-1 and Therapeutic Uses Thereof
 
Number: 20070155686
 
Filed: June 27, 2006
 
Lead Inventor: Akin Akinc, Alnylam Pharmaceuticals
 
“The features of the … invention relate to compounds, compositions, and methods useful for modulating the expression of HIF-1 alpha, such as by the mechanism of RNA interference,” the patent application’s abstract states. “The compounds and compositions include [RNAi] agents that can be unmodified or chemically modified.”
 

 
Title: Compositions and Methods for Generating Short Double-Stranded RNA Using Mutated RNase III
 
Number: 20070155684
 
Filed: Jan. 21, 2005 PCT Filed: Jan. 21, 2005
 
Lead Inventor: Claude Maina, New England Biolabs
 
“Compositions and methods are provided [in the patent application] for preparing an hsiRNA mixture and for silencing of gene expression in vivo,” its abstract states. “The composition relates to a mutant Rnase III. The methods are directed to reacting a preparation of dsRNA with an effective amount of a mutant RNAse III to produce the hsiRNA mixture.”
 

 
Title: Nanoparticles for Delivery of Nucleic Acids and Stable Double-Stranded RNA
 
Number: 20070155658
 
Filed: Nov. 7, 2006
 
Lead Inventor: Steven Quay, Nastech Pharmaceuticals
 
The patent application, its abstract states, claims “nanoparticles of double-stranded nucleic acid complexed [around] a complexing agent such as the melamine derivatives of formulae I and II, preferably forming a trimeric nucleic acid complex. In alternative embodiments, polyarginine or a polymer of Gln and Asn further complexed with the double-stranded nucleic acid complex. In a preferred embodiment, the … nucleic acid is a double stranded RNA having 15 to 30 base pairs suitable for RNA interference,” the abstract adds. “In another aspect of the invention, a dsRNA is produced in which all of the uridines are changed to 5-methyluridine. Preferably, the resultant dsRNAs have 15 to about 30 base pairs and are suitable for RNA interference.”
 

 
Title: System and Method for Identification of microRNA Target Sites and Corresponding Target microRNA Sequences
 
Number: 20070154896
 
Filed: Feb. 10, 2006
 
Lead Inventor: Tien Huynh, International Business Machines
 
The patent application, its abstract states, claims “a method for determining whether a nucleotide sequence contains a microRNA binding site and which microRNA will bind thereto. … For example, in one aspect of the invention, a method for determining whether a nucleotide sequence contains a microRNA binding site and which microRNA sequence will bind thereto is comprised of the following steps: one or more patterns are generated by processing a collection of known mature microRNA sequences; the reverse complement of each generated pattern is then computed; one or more attributes are then assigned to the reverse complement of the one or more generated patterns,” it notes.
 
“The one or more patterns that correspond to a reverse complement having one or more assigned attributes that satisfy at least one criterion are thereafter sub-selected,” the abstract adds. Each sub-selected pattern is then used to analyze the nucleotide sequence, such that a determination is made whether the nucleotide sequence contains a microRNA binding site and which microRNA sequence will bind thereto.”

The Scan

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.